Open access
Sep 2026
Long-term atogepant for treatment-resistant migraine in real-world clinical practice: 12-month results (gema project)
Short- and mid-term real-world data support the effectiveness of atogepant for migraine prevention, but evidence beyond 6 months remains scarce. This study evaluated the 12-month effectiveness, safety, persistence, and predictors of response in a large treatment-resistant migraine cohort. This prospective...
A. Gago-Veiga, A. Lopez-Rodriguez, Blanca Hoyas Cruz et al.
· The Journal of Headache and... · 0 citations